Phosphodiesterase PDE3 blunts the positive inotropic and cyclic AMP enhancing effects of CGP12177 but not of noradrenaline in rat ventricle

British Journal of Pharmacology

Volumn 147, Issue 2, 2006, Pages 158-163

  Vargas, Maria Luisa ^a   Hernandez, Jesus ^a   Kaumann, Alberto J ^b  

^a UNIVERSITY OF MURCIA   (Spain)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

cAMP and contractile force; CGP12177; Noradrenaline; Phosphodiesterases 3 and 4; Rat ventricle

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; BETA 1 ADRENERGIC RECEPTOR; CILOSTAMIDE; CYCLIC AMP; NORADRENALIN; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PROPRANOLOL; ROLIPRAM;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DRUG EFFECT; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; HEART MUSCLE CONTRACTILE FORCE; HEART STIMULATION; INOTROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; RAT;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADRENERGIC BETA-1 RECEPTOR AGONISTS; ANIMALS; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HEART VENTRICLES; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; NOREPINEPHRINE; PROPANOLAMINES; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA-1; ROLIPRAM; STIMULATION, CHEMICAL; VENTRICULAR FUNCTION;

EID: 31444450781     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706498     Document Type: Article

References (35)

1. 1-adrenoceptor. Mol. Pharmacol., 63, 1312-1321.
2. BEAVO, J.A. (1995). Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev., 75, 725-748.
3. COLLADO, M.C., BELETA, J., MARTINEZ, E., MIRALPEIX, M., DOMENECH, T., PALACIOS, J.M. & HERNANDEZ, J. (1998). Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor. Br. J. Pharmacol., 123, 1047-1054.
4. 1-padrenergic receptor. Am. J. Physiol., 43, E199-E202.
5. 1-adrenoceptors and interaction with β-blockers. Naunyn-Schmiedeberg's Arch. Pharmacol., 369, 525-532.
6. 1- adrenoceptors. Br. J. Pharmacol., 142, 51-56.
7. 1- adrenoceptor in human atrium and recombinant receptors. Naunyn-Schmiedeberg's Arch. Pharmacol., 368, 496-503.
8. JUAN-FITA, M.J., VARGAS, M.L. & HERNANDEZ, J. (2005). The phosphodiesterase 3 inhibitor cilostamide enhances inotropic responses to glucagon but not to dobutamine in rat ventricular myocardium. Eur. J. Pharmacol., 512, 207-213.
9. JUAN-FITA, M.J., VARGAS, M.L., KAUMANN, A.J. & HERNANDEZ-CASCALES, J. (2004). Rolipram reduces the inotropic tachyphylaxis of glucagon in rat ventricular myocardium. Naunyn-Schmiedebergs Arch. Pharmacol., 370, 324-329.
10. 2+ channels by β-adrenergic agonists. Proc. Natl. Acad. Sci. U.S.A., 93, 295-299.
11. KATANO, Y. & ENDOH, M. (1992). Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone and isobutylmethylxanthine. J. Cardiovasc. Pharmacol., 20, 715-722.
12. KAUFFMAN, R.F., CROWE, V.G., UTTERBACK, B.G. & ROBERTSON, D.W. (1986). LY195114: a potent, selective inhibitor of cyclic nucleotide phosphodiesterases located in the sarcoplasmic reticulum. Mol. Pharmacol., 30, 609-616.
13. KAUMANN, A.J. (1983). Cardiac β-adrenoceptors - experimental viewpoints. Z. Kardiol., 72, 63-82.
14. KAUMANN, A.J. (1989). Is there a third heart β-adrenoceptor? Trends Pharmacol. Sci., 10, 316-320.
15. KAUMANN, A.J. (1996). CGP12177-induced increase of human atrial contraction through a putative third β-adrenoceptor. Br. J. Pharmacol., 117, 93-98.
16. s protein-coupled receptors in human heart. In: The Pharmacology of Functional, Biochemical, and Recombinant Receptor Systems. Handbook of Experimental Pharmacology, eds. Kenakin, T. & Angus, J.A. Vol. 148, pp. 73-116. Berlin, Heidelberg, New York: Springer.
17. 4- adrenoceptor pharmacology. Naunyn-Schmiedeberg's Arch. Pharmacol., 363, 87-93.
18. KAUMANN, A.J. & LYNHAM, J.A. (1997). Stimulation of cyclic AMP-dependent protein kinase in rat atria by (-)-CGP12177 through an atypical β-adrenoceptor. Br. J. Pharmacol., 129, 1187-1189.
19. 3-adrenoceptor and is coupled to a cyclic AMP-dependent pathway in rat and human myocardium. Br. J. Pharmacol., 120, 102p.
20. 3-adrenoceptor in the rat. Br. J. Pharmacol., 118, 2085-2098.
21. 3-adrenoceptor knock out mice. Mol. Pharmacol., 53, 670-675.
22. 1-adrenergic receptors. J. Pharmacol. Expl. Ther., 294, 923-932.
23. 4-adrenoceptor pharmacology. Br. J. Pharmacol., 141, 813-824.
24. 1-adrenoceptor in ferret ventricular myocardial myocardium. Br. J. Pharmacol., 135, 451-461.
25. MONGILLO, M., MCSORLEY, T., EVELLIN, S., SOOD, A., LISSANDRON, V., TERRIN, A., HUSTON, E., HANNAWACKER, A., LOHSE, M.J., POZZAN, T., HOUSLAY, M.D. & ZACCOLO, M. (2004). Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ. Res., 95, 67-75.
26. MOVSESIAN, M.A., SMITH, C.J., KRALL, J., BRISTOW, M.R. & MANGANIELLO, V.C. (1991). Sarcoplasmic reticulum-associated cyclic adenosine 5′-monophosphate phosphodiesterase activity in normal and failing human hearts. J. Clin. Invest., 88, 15-19.
27. NICHOLSON, D., CHALLISS, R.A. & SHAHID, M. (1991). Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol. Sci., 12, 19-27.
28. 1-adrenoceptors. J. Recept. Signal Transduct. Res., 16, 1-23.
29. RICH, T.C., FAGAN, K.A., TSE, T.E., SCHAACK, J., COOPER, D.M.F. & KARPEN, J.W. (2001). A uniform extracellular stimulus triggers distinct cAMP signals in different compartments of a simple cell. Proc. Natl. Acad. Sci. U.S.A., 98, 13049-13054.
30. 4-adrenoceptor in rat atrium. Br. J. Pharmacol., 123, 371-380.
31. 3H]-CGP12177 binding. Br. J. Pharmacol., 128, 1445-1460.
32. 1-adrenoceptor. Naunyn-Schmiedeberg's Arch. Pharmacol., 367, 10-21.
33. STAEHELIN, M., SIMONS, P., JAEGGI, K. & WIGGER, H. (1983). A hydrophillic beta-adrenergic radioligand reveals high affinity binding of agonists to intact cells. J. Biol. Chem., 258, 3496-3502.
34. SUDO, T., TACHIBANA, K., TOGA, K., TOCHIZAWA, S., INOUE, Y., KIMURA, Y. & HIDAKA, H. (2000). Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem. Pharmacol., 59, 347-356.
35. VERDE, I., VANDECASTEELE, G., LEZOUALC'H, F. & FISCHMEISTER, R. (1999). Characterization of the cylic nucleotide phosphodiesterases subtypes in the regulation of the L-type calcium current in rat ventricular myocytes. Br. J. Pharmacol., 127, 65-74.